Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.57 USD | +2.79% | +0.78% | -25.74% |
May. 31 | Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema | MT |
May. 31 | Transcript : Ionis Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.74% | 5.48B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study